AbbVie Inc. (FRA:4AB)
Germany · Delayed Price · Currency is EUR | Market Cap | 337.40B +3.7% |
| Revenue (ttm) | 52.09B +8.6% |
| Net Income | 3.57B -1.2% |
| EPS | 2.01 -1.3% |
| Shares Out | n/a |
| PE Ratio | 94.64 |
| Forward PE | 15.44 |
| Dividend | 5.75 (3.03%) |
| Ex-Dividend Date | Jan 16, 2026 |
| Volume | 60 |
| Average Volume | 64 |
| Open | 192.00 |
| Previous Close | 193.00 |
| Day's Range | 190.00 - 192.00 |
| 52-Week Range | 147.00 - 209.50 |
| Beta | n/a |
| RSI | 50.24 |
| Earnings Date | Feb 4, 2026 |
About AbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]
Financial Performance
In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.23 billion, a decrease of -0.28%.
Financial numbers in USD Financial StatementsNews
EAGLE GLOBAL ADVISORS LLC Buys 158 Shares of AbbVie Inc (ABBV)
EAGLE GLOBAL ADVISORS LLC Buys 158 Shares of AbbVie Inc (ABBV)
Vanguard Mega Cap Index Fund Buys 38,875 Shares of AbbVie Inc (ABBV)
Vanguard Mega Cap Index Fund Buys 38,875 Shares of AbbVie Inc (ABBV)
Migdal Insurance & Financial Holdings Ltd. Buys 75,103 Shares of AbbVie Inc (ABBV)
Migdal Insurance & Financial Holdings Ltd. Buys 75,103 Shares of AbbVie Inc (ABBV)
Vanguard S&P 500 Growth Index Fund Buys 13,772 Shares of AbbVie Inc (ABBV)
Vanguard S&P 500 Growth Index Fund Buys 13,772 Shares of AbbVie Inc (ABBV)
Oversea-Chinese Banking CORP Ltd Sells 1,892 Shares of AbbVie Inc (ABBV)
Oversea-Chinese Banking CORP Ltd Sells 1,892 Shares of AbbVie Inc (ABBV)
Leelyn Smith, LLC Sells 821 Shares of AbbVie Inc (ABBV)
Leelyn Smith, LLC Sells 821 Shares of AbbVie Inc (ABBV)
Beyond the Balance Sheet: What SWOT Reveals About AbbVie Inc (ABBV)
Beyond the Balance Sheet: What SWOT Reveals About AbbVie Inc (ABBV)
Barclays Initiates Coverage on ABBV with Overweight Rating | ABBV Stock News
Barclays Initiates Coverage on ABBV with Overweight Rating | ABBV Stock News
Dividend Roundup: Halliburton, AbbVie, Johnson & Johnson, Delta Air Lines, and more
Salomon & Ludwin, LLC Sells 494 Shares of AbbVie Inc (ABBV)
Salomon & Ludwin, LLC Sells 494 Shares of AbbVie Inc (ABBV)
Vanguard Russell 3000 Index Fund Buys 2,700 Shares of AbbVie Inc (ABBV)
Vanguard Russell 3000 Index Fund Buys 2,700 Shares of AbbVie Inc (ABBV)
Vanguard Mega Cap Value Index Fund Buys 35,225 Shares of AbbVie Inc (ABBV)
Vanguard Mega Cap Value Index Fund Buys 35,225 Shares of AbbVie Inc (ABBV)
FDA Approval For AbbVie/AstraZeneca's Combination Treatment Could Set New Standard For Slow Growing Blood Cancer
On Friday, the U.S. Food and Drug Administration (FDA) approved AbbVie Inc.'s (NYSE: ABBV) combination treatment for chronic lymphocytic leukemia (CLL). The FDA has approved the combination of Vencle...
FDA Approves AbbVie's (ABBV) New CLL Treatment Regimen
FDA Approves AbbVie's (ABBV) New CLL Treatment Regimen
AbbVie wins FDA approval for Venclexta-acalabrutinib combo in first-line chronic lymphocytic leukemia
FDA Approves AbbVie's (ABBV) New Treatment Combo for Leukemia
FDA Approves AbbVie's (ABBV) New Treatment Combo for Leukemia
U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
First all-oral, fixed-duration combination regimen approved for previously untreated patients with CLL Approval supported by data from the Phase 3 AMPLIFY trial Regimen offers another option for the p...
IWF, TSLA, ABBV, NFLX: ETF Inflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 Growth ETF (Symbol: IWF) where we have detected a...
3 Stocks to Buy and Hold for 2026 and Beyond
AbbVie is a Dividend King, poised for strong growth with Rinvoq and Skyrizi. Eli Lilly has taken control of the obesity drug market, with major possibilities ahead.
AbbVie (ABBV) Maintains Quarterly Dividend of $1.73/Share
AbbVie (ABBV) Maintains Quarterly Dividend of $1.73/Share
AbbVie declares $1.73 dividend
AbbVie (ABBV) declares a $1.73 quarterly dividend (3.04% forward yield) payable May 15.
AbbVie Declares Quarterly Dividend
NORTH CHICAGO, Ill., Feb. 19, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.73 per share.
Here's How Much $1000 Invested In AbbVie 10 Years Ago Would Be Worth Today
AbbVie (NYSE: ABBV) has outperformed the market over the past 10 years by 1.83% on an annualized basis producing an average annual return of 15.34%. Currently, AbbVie has a market capitalization of $...
Vanguard Russell 1000 Index Fund Buys 6,426 Shares of AbbVie Inc (ABBV)
Vanguard Russell 1000 Index Fund Buys 6,426 Shares of AbbVie Inc (ABBV)
2 Dividend Stocks to Hold for the Next 5 Years
AbbVie is a Dividend King that's a successful player in multiple critical therapeutic areas. Enbridge is an energy infrastructure leader with an especially attractive dividend.